News articles about PAREXEL International (NASDAQ:PRXL) have been trending somewhat positive this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. PAREXEL International earned a news sentiment score of 0.09 on Accern’s scale. Accern also assigned media stories about the medical research company an impact score of 48.3749378811581 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
PRXL remained flat at $$88.08 during trading on Friday. PAREXEL International has a 52 week low of $51.16 and a 52 week high of $88.10. The company has a quick ratio of 1.45, a current ratio of 1.45 and a debt-to-equity ratio of 1.01.
About PAREXEL International
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.
Receive News & Ratings for PAREXEL International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International and related companies with MarketBeat.com's FREE daily email newsletter.